UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 7, 2011

MEDICINOVA, INC.

(Exact name of Registrant as Specified in Its Charter)

DELAWARE (State or Other Jurisdiction of Incorporation) 001-33185 (Commission File Number)

(IRS Employer Identification No.)

33-0927979

4350 LA JOLLA VILLAGE DRIVE, SUITE 950, SAN DIEGO, CA (Address of Principal Executive Offices)

(Zip C

Registrant's telephone number, including area code: (858) 373-1500

Not Applicable (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

D Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

D Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

92122 (Zip Code)

Item 7.01. Regulation FD Disclosure.

On January 7, 2011, MediciNova, Inc. (the "Registrant") updated the slide presentation to be used by the Registrant at investor meetings. A copy of the revised slide presentation is attached hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K being provided under this Item 7.01, including Exhibit 99.1 furnished herewith, is being furnished and shall not be deemed "filed" for any purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such Section. The information in this current report on Form 8-K shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Slide Presentation of the Registrant.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, MediciNova has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDICINOVA, INC.

Date: January 7, 2011

/S/ SHINTARO ASAKO

Shintaro Asako Chief Financial Officer

By: Name: Title:



Accelerating the global development and commercialization of innovative pharmaceuticals



Forward-Looking Statements

Statements in this presentation that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding MediciNova's clinical trials supporting the safety and efficacy of its product candidates and the potential novelty of such product candidates as treatments for disease, plans and objectives for clinical trials and product development, strategies, future performance, expectations, assumptions, financial condition, liquidity and capital resources. These forward-looking statements may be preceded by, followed by or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," or similar expressions. Actual results or events may differ materially from those expressed or implied in any forward-looking statements due to various factors, including the risks and uncertainties inherent in clinical trials and product development and commercialization, such as the uncertainty in results of clinical trials for product candidates, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials and the timing, cost and design of future clinical trials and research activities; the timing of expected filings with the FDA; MediciNova's failure to execute strategic plans or strategies successfully; MediciNova's collaborations with third parties; MediciNova's ability to realize the anticipated strategic and financial benefits from its acquisition of Avigen, Inc., to integrate the two ibudilast development programs and to pursue discussions with potential partners to secure a strategic collaboration to advance the clinical development of the combined development program; the availability of funds to complete product development plans and MediciNova's ability to raise sufficient capital when needed, or at all; MediciNova's ability to comply with the covenants in its financing agreements; intellectual property or contract rights; and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including MediciNova's annual report on Form 10-K for the year ended December 31, 2009 and its subsequent periodic reports on Forms 10-Q and 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of January 7, 2010. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.



Corporate Overview: MediciNova, Inc.

MediciNova Overview:

- Founded in September 2000
- Headquartered in San Diego, CA
 - Additional office in Tokyo, Japan
- Dual-listing on NasdaqGM as MINDO saka Securities Exchange as 4875
- \$65.5 million Market Cap (NasdaqGM) as of 1/05/2011

Development Company Focused on Differentiated Product Candidates

• Unique access to differentiated, potentially high-value assets primarily from Japanese alliances (Kyorin, Kissei, Mitsubishi Tanabe Pharma, Meiji)

New Approaches to Treat Serious Medical Conditions:

- MN-221: Intravenous (IV) acute asthma and COPD candidate
 - Potential \$1 billion+ combined market opportunity worldwide*

3


• MN-166: oral multiple sclerosis, neuropathic pain, drug addiction candidate

*Source: Internal MediciNova projections




\bigcirc

MN-221 for Exacerbations of Acute Asthma and COPD



Acute Asthma Treatment Flow in Emergency Departments in the U.S.





Limitations of Current Therapies

What are the limitations of current therapies for acute exacerbations of asthma?

Limitations of Inhaled Therapies:

- Bronchoconstrictionflammatioandbronchoconstrictionsultininsufficienation flowtogetgooddrugdepositioin thelungs
- MucuPlugFormationmucussecretioandtheformatioofthickmucuplugs cancausepersistentirflowlimitation
- Albuterdion-Respondersotallpatientspenefitromalbuterol

Limitations of Current Intravenous Therapies:

 Safety currentlavailableption (e.g.epinephrinterbutaline) ave unacceptablardiovasculaisks at dosesused

6







MN-221: Target Product Profile

*MN-221 Indication: Treatment of bronchis***pasiens***ts with acute exacerbations of asthma or COPD. It is administered adjunctive to standard of care by intravenous infusion.*

- A well-tolerate potents elective β_2 -agonist which sonly a partial agonist β_1 .
- Abronchodilatidgrationofactionthatis longethanSABAsandshortethan LABAs.
- Provides additional bronchodivation used in addition to the standard treatments of inhaled albuterol, inhaled ipratropium, and steroids.

8

- Reduces the hospitalization rate among patients treated with MN-221.
- Noclinicaadverseffectsvheraddedostandarofcare(SOC).






MN-221 Clinical Trials

	Completed				Ongoing
Study	CL-004	CL-005	CL-006	CL-010	CL-007
Indication	Mild-to-moder Asthmatics	Moderate-to- ate Severe Asthmatics	Acute Exacerbation of Asthma	Moderate-to- s Severe COPD patien	Exacerbations
FEYٍ (Entry Criteri	FEY≥60%	75%⊵ FEY ≥ 40%	FEY_≤55%	80%⊵ FEY ≥ 30%	FEY_≤50%
Number of Patients	23	17	29	48	200
Number of Sites	4	4	8	6	~20
Doses Teste Compared t Placebo	⁽¹ 150 2/0 /50	1,125 µg ove	over 15 min;	300, 600, 120	01200 μg over 1-hr

Note: CL-004, CL-005, CL-010 located in clinical sites. CL-006, CL-007 located in emergency departments. MEDICINOVA
9
MEDICINOVA

MN-221-CL-006 Mean Change in FEYand Differences in Hospitalization Rate





MN-221-CL-007: **Study Design**

- Randomized, placebo-controlled, double-blind, multi-center Phase II clinical trial
- Upto200patientswithsevereacuteexacerbationssasthma(FEV_= 50% predicted) at multiple Emergency Department sites in the United States
- Dose Groups (up to 100 patients/group):
 - 1,200 μgf MN-221 over 1 hour (600 μg minutes; 600 μgext 45 minutes)
 - Placebo
- Patients will receive SOC treatment in addition to adjunctive treatment with MN-221 or placebo
- PrimarefficacendpointvillbeimprovemeintFEV₁ (%predicted)t3hours
 - The study is designed to have 80% power to detect a treatment difference of 5 percentageointsin FEV1(%predicted)/hercomparinty/N-221+SOC to Placebo + SOC at a two sided a-level of 0.05.
- Anticipated completion in 2H, 2011*

*Anticipated completion date based on current projections Note: Development plans / timelines for MN-221 clinical trials are subject to change

© MediciNova, Inc. 2011





Ibudilast for the Treatment of MS, Neuropathic Pain, & Drug Addiction

Ibudilast (MN-166/AV411)

- Oral administration
- Safe and well-tolerated (approved in Japan/Korea with over 3.2 rexibos upration that the safe and well-tolerated (approved in Japan/Korea with over 3.2 rexibos upration to the safe and well-tolerated (approved in Japan/Korea with over 3.2 rexibos upration to the safe and well-tolerated (approved in Japan/Korea with over 3.2 rexibos upration to the safe and well-tolerated (approved in Japan/Korea with over 3.2 rexibos upration to the safe and well-tolerated (approved in Japan/Korea with over 3.2 rexibos upration to the safe and well-tolerated (approved in Japan/Korea with over 3.2 rexibos upration to the safe and well-tolerated (approved in Japan/Korea with over 3.2 rexibos upration to the safe and well-tolerated (approved in Japan/Korea with over 3.2 rexibos upration to the safe and well-tolerated (approved in Japan/Korea with over 3.2 rexibos upration to the safe and well-tolerated (approved in Japan/Korea with over 3.2 rexibos upration to the safe and well-tolerated (approved in Japan/Korea with over 3.2 rexibos upration to the safe and well-tolerated (approved in Japan/Korea with over 3.2 rexibos upration to the safe and well-tolerated (approved in Japan/Korea with over 3.2 rexibos upration to the safe and to the safe and
- Mechanism(s) of Action primarily Inhibition of Microphage Migration Inhibitor Factor (MIF), PDE-4,10 inhibition; Attenuation of Glial Cell Activation

Clinical Safety & Preliminary Efficacy

- Completed Phase 2 Multiple Sclerosis Proof-of-Concept study (30 and 60 mg/d, predominately RRMS pts.)
- Completed Phase 1b/2a trial in Diabetic Neuropathic Pain (40) d) nd
- Completed Phase 1b/2a clinical trial in Opioid Withdrawal & Analgesia (40 and 80 mg/d) (Columbia Univ/NYSPI via NIDA funding)
- Ongoing Phase 1b Methamphetamine interaction trial (UCLA via NIDA funding)
- Additional Supporting Data
 - 3 completed Phase 1 clinical trials
 - Dosing up to 100 mg single dose & 100 mg daily (50 mg twice/day)
 - ~400 subjects treated with MN-166/AV411 to date (safe & well-tolerate)

© MediciNova, Inc. 2011

12

MEDIĈINOVA



Ibudilast (MN-166/AV411): Status for Each Indication

Status for Chronic Pain:

- MN-166/AV411 is enabled to go directly to Phase 2b clinical development
- MN-166/AV411echanisorfactionsnoveandthuscomplimentatrycurrenpaintreatments, and has both stand-alone and adjunctive utilities
- Majority of potential pharateners are strategically committed to new pain therapies
- MN-166/AV411 has an attractive development timeline and long term exclusivity

Status for Drug Addiction/Ophioindirawal:

- Announced positive safety/efficacy results from Phase 1b/2a stWdyhidr@wadi(12/10)
- UCLA initiated Phasetlloly for Methamphetamine Addiction (9/10)

Status for Multiple Sclerosis:

- MN-166/AV411 requires significant funding for future trials
- Phase 2 data were at doses that are below maximum utility
- Most attractive option may be Progressive MS which would deditioned Phase 2b clinical trial

© MediciNova, Inc. 2011






Ibudilast Neuropathic Pain Market Opportunity

Pfizer Ili Lilly Pfizer	9.1 Million 14.7 Million 23.4 Million	 million neuropathic pain patients the U.S. and #0llion worldwide MN-166 has a different mechanism of action than curren marketed neuropathic pain therenice
-		mechanism of action than curren marketed neuropathic pain
Pfizer	23.4 Million	
		therapies
Total	47.1 Million	MN-166 has potential to captur
Annual Marke pportunity:	^t ∼\$8.0 Billiðn	substantial market share in the neuropathic pain market
Pfizer Quarterly Rep nded Prices	ports	
	nnual Marke portunity: Pfizer Quarterly Rej Ided Prices	nnual Market portunity: [•] \$8.0 Billio n







Most Likely Scenario for Ibudilast's Development

Collaboration Structure with Plantmer:

- **1. Shared Risk**
- 2. All indications; Ibudila/stalogues
- 3. Option Agreement around Phase 2b Diabetic Peripheral Neuropathic Painand/oProgressiveStrialwithExclusiveicense, Development Milestones, Royalties, Sales Milestones.

Sustain NIDA-sponsored Drug Addiction development

Consider Investigator-sponsored Neurological Trials





Commercially-Attractive Diversified Portfolio

Core Candidates	Preclinical	Phase I	Phase II	Phase III
MN-166 (MS and other CNS Disorders)	Kyorin 🕗	Pain/Addiction	MS	
MN-221 (Exacerbations of Acute Asthma/COPD)	KISSE	СОРД	Asthma	
Non-Core Candidates	Preclinical	Phase I	Phase II	Phase III
MN-001 (Bronchial Asthma)	Kyorin 🛇			
MN-305 (Anxiety Disorders)	Mitsubishi Tanabe Pianna			
MN-001 (Interstitial Cystitis)	Kyorin 🕗			
MN-029 (Solid Tumors)				
MN-221 (Preterm Labor)	KISSEI			
MN-246 (Urinary Incontinence)	Witsubishi Tanabe Pranma			
MN-447/462 (Thrombosis)	Meiji			
© MediciNova, Inc. 2011	17		MEL	NOVA



Management Team with Global Experience

Leadership	
Yuichi Iwaki, MD, PhD CEO & President	
Shintaro Asako, CPA Chief Financial Officer	
Kirk Johnson, Ph.D. Chief Scientific Officer	
Michael Coffee Chief Business Officer	
Masatsune Okajima, CMA VP, Head of Japanese Office	1
	_

	Leadership	Years Experienc	e Background	
	Yuichi Iwaki, MD, PhD CEO & President	35	Professor at USC, formerly Professor at Un of Pittsburgh; Advisor to JAFCO, Tanabe	iversity
	Shintaro Asako, CPA Chief Financial Officer	13	KPMG USA (Audit), Arthur Andersen USA	
1	Kirk Johnson, Ph.D. Chief Scientific Officer	21	Avigen, Genesoft Pharmaceuticals, Chiron Corporation	
	Michael Coffee Chief Business Officer	26	Avigen, Amarin Corp., Elan Pharmaceutical Athena Neurosciences	s, N.A.,
	Masatsune Okajima, CMA VP, Head of Japanese Office	A 19	Daiwa Securities SMBC, Sumitomo Capital Securities, Sumitomo Bank	

() MEDIĈINOVA

© MediciNova, Inc. 2011



Investment Highlights

Upcoming Near-Term Business Milestones:

- 1. Secure a global partnership for Ibudilast (MN-166/AV411)
- 2. Secure a strategic partnership for MN-221

Upcoming Clinical Milestones:

MN-221-CL-007 Phase II Study for Acute Exacerbations of Asthma

 Anticipated completion in 2H, 2011*

Completed Milestones in 2010:

- 1. Announced Positive MN-221-CL-010 Phase Ib Study Results in Moderate-to-Severe COPD Patients on March 17, 2010
- 3. Secured \$15M Debt Financing from Oxford Finance Corp.201 May 10,
- 4. Announced Positive Safety and Efficacy data for Ibudilast (MN-166/AV411) Phase Ib/2a Study Results for Opioid Withdrawal and Analgesia on December 13, 2010

*Anticipated completion dates based on current projections © MediciNova, Inc. 2011 19

